281 related articles for article (PubMed ID: 34158843)
1.
Shi Z; Shen J; Qiu J; Zhao Q; Hua K; Wang H
Theranostics; 2021; 11(15):7175-7187. PubMed ID: 34158843
[No Abstract] [Full Text] [Related]
2. Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma.
Zhou X; Xu R; Lu T; Xu R; Wang C; Peng B; Chang X; Shen Z; Wang K; Shi J; Zhao J; Zhang LY
Aging (Albany NY); 2023 Aug; 15(16):8090-8112. PubMed ID: 37578930
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
[TBL] [Abstract][Full Text] [Related]
4. Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Shi Z; Zhao Q; Lv B; Qu X; Han X; Wang H; Qiu J; Hua K
Clin Transl Med; 2021 May; 11(5):e399. PubMed ID: 34047476
[TBL] [Abstract][Full Text] [Related]
5. CXCL10 and CCL5 as feasible biomarkers for immunotherapy of homologous recombination deficient ovarian cancer.
Han Y; Guo Z; Jiang L; Li X; Chen J; Ouyang L; Li Y; Wang X
Am J Cancer Res; 2023; 13(5):1904-1922. PubMed ID: 37293164
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
[TBL] [Abstract][Full Text] [Related]
8. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
10. A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.
Chen Y; Zheng X; Lin J; Gao X; Xiong J; Liu J; Fei Z; Chen C
Oral Oncol; 2022 May; 128():105860. PubMed ID: 35428026
[TBL] [Abstract][Full Text] [Related]
11. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
12. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
13. Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer.
Yang D; Huang FX; Wei W; Li QQ; Wu JW; Huang Y; Li ZL; Zhang HL; Li X; Yuan QE; Chen QS; Feng GK; Rong D; Li JD; Zhu XF
Int J Biol Sci; 2023; 19(6):1846-1860. PubMed ID: 37063431
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
Kim H; Ahn S; Kim H; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim KM; Kim ST
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2427-2435. PubMed ID: 34510272
[TBL] [Abstract][Full Text] [Related]
15. Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy.
Ali U; Vungarala S; Tiriveedhi V
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397152
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
18. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types.
Shi Z; Chen B; Han X; Gu W; Liang S; Wu L
Sci Rep; 2023 Jun; 13(1):8899. PubMed ID: 37264024
[TBL] [Abstract][Full Text] [Related]
19. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
[TBL] [Abstract][Full Text] [Related]
20. Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population.
Hamilton AM; Van Alsten SC; Gao X; Nsonwu-Farley J; Calhoun BC; Love MI; Troester MA; Hoadley KA
Cancer Res Commun; 2023 Jan; 3(1):12-20. PubMed ID: 36968228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]